1. Home
  2. HURA vs WLGS Comparison

HURA vs WLGS Comparison

Compare HURA & WLGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • WLGS
  • Stock Information
  • Founded
  • HURA 2009
  • WLGS 1981
  • Country
  • HURA United States
  • WLGS Hong Kong
  • Employees
  • HURA N/A
  • WLGS N/A
  • Industry
  • HURA
  • WLGS Engineering & Construction
  • Sector
  • HURA
  • WLGS Consumer Discretionary
  • Exchange
  • HURA Nasdaq
  • WLGS Nasdaq
  • Market Cap
  • HURA 96.5M
  • WLGS 98.9M
  • IPO Year
  • HURA N/A
  • WLGS 2023
  • Fundamental
  • Price
  • HURA $3.48
  • WLGS $0.25
  • Analyst Decision
  • HURA Strong Buy
  • WLGS
  • Analyst Count
  • HURA 2
  • WLGS 0
  • Target Price
  • HURA $12.00
  • WLGS N/A
  • AVG Volume (30 Days)
  • HURA 272.1K
  • WLGS 4.8M
  • Earning Date
  • HURA 05-15-2025
  • WLGS 04-15-2025
  • Dividend Yield
  • HURA N/A
  • WLGS N/A
  • EPS Growth
  • HURA N/A
  • WLGS N/A
  • EPS
  • HURA N/A
  • WLGS 0.02
  • Revenue
  • HURA N/A
  • WLGS $7,272,879.00
  • Revenue This Year
  • HURA N/A
  • WLGS N/A
  • Revenue Next Year
  • HURA $221.29
  • WLGS N/A
  • P/E Ratio
  • HURA N/A
  • WLGS $14.79
  • Revenue Growth
  • HURA N/A
  • WLGS 66.93
  • 52 Week Low
  • HURA $1.80
  • WLGS $0.23
  • 52 Week High
  • HURA $14.60
  • WLGS $9.66
  • Technical
  • Relative Strength Index (RSI)
  • HURA N/A
  • WLGS 27.41
  • Support Level
  • HURA N/A
  • WLGS $0.23
  • Resistance Level
  • HURA N/A
  • WLGS $5.85
  • Average True Range (ATR)
  • HURA 0.00
  • WLGS 0.37
  • MACD
  • HURA 0.00
  • WLGS -0.30
  • Stochastic Oscillator
  • HURA 0.00
  • WLGS 0.27

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About WLGS Wang & Lee Group Inc.

WANG & LEE Group Inc operates as an investment holding company. The firm conducts its primary operations through its indirectly wholly owned subsidiary WANG and LEE CONTRACTING LIMITED (WLHK). WLHK provides contract engineering, installation, and out-fitting of the following products and services: low voltage (220v/phase 1 or 380v/phase 3) electrical systems, mechanical ventilation and air-conditioning systems (MVAC), fire safety systems, and water supply and sewage disposal systems.

Share on Social Networks: